BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1232@pharmaconomics
DTSTAMP:20260707T053602Z
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260326
SUMMARY:NSRX Phase 2 — NS002
DESCRIPTION:Phase 2 trial results for NS002 in anaphylaxis are due Mar 25\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/2029039/000149315226012663/ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1232
URL:https://www.pharmaconomics.com/e/1232
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NSRX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR